SynthesisBMC neurology2024
Association between metabolic syndrome and the risk of Parkinson's disease: a meta-analysis.
Synthesis in BMC neurology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Metabolic Syndrome and Incidence of Parkinson Disease: A Community-Based Longitudinal Study and Meta-Analysis.Neurology · 2025Pooled it
- Comparative neuroprotective effects of antidiabetic medications on Parkinson's disease risk: a Bayesian network meta-analysis.Journal of global health · 2026Article
- Metabolic syndrome is associated with accelerated brain aging.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Insulin Resistance and Metabolic Dysfunction in Early-Stage Parkinson's Disease: Evidence from a Preliminary Case-Control Study.Journal of clinical medicine · 2026Article
- Risk of Parkinson disease according to metabolic syndrome among Korean adults: an analysis of data from the National Health Insurance-National Sample Cohort.Epidemiology and health · 2026Article
- The olfactory-glymphatic syndrome: linking smell dysfunction, cognitive impairment and sleep disturbances in neuropathological disorders.Frontiers in neuroscience · 2026Review
- Article
- Transcriptomic Alteration in the Brain and Gut of Offspring Following Prenatal Exposure to Corticosterone.Experimental neurobiology · 2025Article
- Exploring the link between estimated glucose disposal rate and Parkinson's disease: cross-sectional and mortality analysis of NHANES 2003-2016.Frontiers in aging neuroscience · 2025Article
- Etiology, Pathophysiology, and Treatment Strategies in the Prevention and Management of Metabolic Syndrome.Archives of internal medicine research · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThere is still a lack of knowledge about the relationship between metabolic syndrome (MetS) and Parkinson's disease (PD). This study aimed to determine whether MetS increases PD risk.
methodsTo identify relevant clinical studies, databases such as PubMed, Embase, and the Cochrane Library were searched in depth from the inception of databases until March 31, 2024. The study evaluated the correlation between MetS and the likelihood of developing PD through the computation of aggregated relative risks (RR) and their respective 95% confidence intervals (CIs) utilizing selnRR and lnRR.
resultsSeven studies were included in our systematic review. The meta-analysis revealed that patients with MetS have a 0.3-fold increased risk of developing PD (p = 0.001). Furthermore, the analysis revealed a positive correlation between central obesity and the incidence of PD, with an RR of 1.19 (95% CI, 1.16-1.22; p = 0.001), as well as a greater risk of PD in patients with elevated blood pressure, with an RR of 1.13 (95% CI, 1.07-1.19; p = 0.001); elevated serum triglyceride levels, with an RR of 1.09 (95% CI, 1.02-1.15; p = 0.001); lower serum HDL cholesterol levels, with an RR of 1.21 (95% CI, 1.15-1.28; p = 0.001); and elevated plasma fasting glucose levels, with an RR of 1.18 (95% CI, 1.11-1.26; p = 0.001).
conclusionMetS can contribute to the incidence of Parkinson's disease, with individual components of MetS demonstrating comparable effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.